Lurbinectedin is a new drug that has been approved for the treatment of small cell lung cancer and relapsed ovarian cancer [1]. However, its use in breast cancer patients is still being studied. According to a recent study published in the Journal of Clinical Oncology [2], Lurbinectedin has shown promising results in patients with metastatic breast cancer. The study reported that Lurbinectedin had a manageable safety profile and showed promising efficacy in patients with metastatic breast cancer. However, the recommended dosage of Lurbinectedin for breast cancer patients is not yet established.

Further clinical trials are required to determine the optimal dosage of Lurbinectedin for breast cancer patients. In the meantime, patients with breast cancer should consult their oncologist regarding the use of Lurbinectedin and its potential benefits and risks.

In conclusion, Lurbinectedin is a new drug that has shown promising results in patients with metastatic breast cancer. However, the recommended dosage of Lurbinectedin for breast cancer patients is not yet established, and further clinical trials are required to determine the optimal dosage. Patients with breast cancer should consult their oncologist regarding the use of Lurbinectedin and its potential benefits and risks.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://pubmed.ncbi.nlm.nih.gov/36455505/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/